Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept in IgA nephropathy (ORIGIN / ORIGIN 3)
2023-503772-24-00Phase 3Authorised
- Sponsor
- Vera Therapeutics
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Atacicept with Placebo comparator (2 arms). Planned start Sep 2021; status: authorised.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-503772-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503772-24-00.